Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

By afschroeder • July 8, 2025

Kumaraswamy A, Hu YM, Yates JA, Zhang C, Rodansky E, Khokhani D, Flores D, Duan Z, Zhang Y, Tabatabaei S, Slottke R, Ye S, Lara P, Foye A, Ryan CJ, Quigley DA, Huang J, Aggarwal R, Reiter RE, Wicha MS, Beer TM, Rettig M, Gleave M, Evans CP, Witte ON, Stuart JM, Thomas GV, Feng FY, Small EJ, Xia Z, Alumkal JJ. Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer. NPJ Precis Oncol. 2025 Jul 7;9(1):223. doi: 10.1038/s41698-025-01002-8. PMID: 40624104.

Tags: Hematology/Oncology, Publications, Veterans Administration

Related Posts

Differences in treatment decision-making for non-small cell lung cancer among patients and physicians, by race and ethnicity

Dwyer Orr L, Vadagam P, Vanderpoel J, Patel MI, Basu Roy U, Ledezma B, Yung M, Deering KL, Kulbokas V, Feldman J, Gray JE. Differences[...]

IDH2 mutation is associated with favorable outcome among older adults with newly diagnosed acute myeloid leukemia treated with hypomethylating agent-based therapy

Hoff FW, Huang Y, Welkie RL, Swords RT, Traer E, Stein EM, Lin TL, Baer MR, Duong VH, Blum WG, Arellano ML, Stock W, Odenike[...]

Real world outcomes of patients with secondary acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation after induction with liposomal daunorubicin-cytarabine (CPX-351)

Ngo D, Kaleka G, Yang D, Mokhtari S, Tinajero J, Marcucci G, Nakamura R, Pullarkat V, Oliai C, Salhotra A. Real world outcomes of patients[...]